Evidence map›Paper›PMID 36203656›Full record

ArticleFrontiers in public health2022

Molecular classification of human papillomavirus-positive cervical cancers based on immune signature enrichment.

Guanghui Song, Jiangti Luo, Shaohan Zou, Fang Lou, Tianfang Zhang, Xiaojun Zhu, Jianhua Yang, Xiaosheng Wang

Abstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Current issues in molecular biology · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guanghui SongDepartment of Gynecology and Obstetrics, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Jiangti LuoBiomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Shaohan ZouDepartment of Gynecology and Obstetrics, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Fang LouDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Tianfang ZhangDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaojun ZhuDepartment of Gynecology and Obstetrics, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jianhua YangDepartment of Gynecology and Obstetrics, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Xiaosheng WangBiomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Human papillomavirus-positive (HPV+) cervical cancers are highly heterogeneous in clinical and molecular characteristics. Thus, an investigation into their heterogeneous immunological profiles is meaningful in providing both biological and clinical insights into this disease. Methods: Based on the enrichment of 29 immune signatures, we discovered immune subtypes of HPV+ cervical cancers by hierarchical clustering. To explore whether this subtyping method is reproducible, we analyzed three bulk and one single cell transcriptomic datasets. We also compared clinical and molecular characteristics between the immune subtypes. Results: Clustering analysis identified two immune subtypes of HPV+ cervical cancers: Immunity-H and Immunity-L, consistent in the four datasets. In comparisons with Immunity-L, Immunity-H displayed stronger immunity, more stromal contents, lower tumor purity, proliferation potential, intratumor heterogeneity and stemness, higher tumor mutation burden, more neoantigens, lower levels of copy number alterations, lower DNA repair activity, as well as better overall survival prognosis. Certain genes, such as Conclusion: HPV+ cervical cancers are divided into two subgroups based on their immune signatures' enrichment. Both subgroups have markedly different tumor immunity, progression phenotypes, genomic features, and clinical outcomes. Our data offer novel perception in the tumor biology as well as clinical implications for HPV+ cervical cancer.

Indexed as

AlphapapillomavirusPapillomavirus InfectionsUterine Cervical NeoplasmsCaspase 7ChemokinesCytokinesFemaleHumansNF-kappa BPhosphatidylinositol 3-KinasesReceptors, Antigen, B-CellReceptors, CytokineSTAT5 Transcription FactorTumor Suppressor Protein p53Caspase 7ChemokinesCytokinesNF-kappa BPhosphatidylinositol 3-KinasesReceptors, Antigen, B-CellReceptors, CytokineSTAT5 Transcription FactorTumor Suppressor Protein p53human papillomavirus-positive cervical cancerimmunological classificationimmunotherapymachine learningmulti-omics analysis

Identifiers

PMID36203656
PMCPMC9531689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.